<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144641">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01941485</url>
  </required_header>
  <id_info>
    <org_study_id>A01354</org_study_id>
    <nct_id>NCT01941485</nct_id>
  </id_info>
  <brief_title>WaveLight® Refractive Flap Accuracy Study</brief_title>
  <official_title>A Prospective, Global, Multi-Center Study to Evaluate Longitudinal Flap Accuracy on Subjects Undergoing Myopic Refractive Surgery Using the WaveLight® Refractive Suite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>Greece: Ethics Committee</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate outcomes on subjects undergoing myopic refractive
      surgery using the WaveLight® Refractive Suite.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Corneal flap thickness as assessed by ocular coherence tomography (OCT)</measure>
    <time_frame>Day 1 (post operative)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The thickness of the corneal flap will be assessed by OCT (ie, an imaging method using light to capture three-dimensional images). Corneal flap thickness is measured in microns.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opaque bubble layer (OBL) development</measure>
    <time_frame>Day 0 (operative day)</time_frame>
    <safety_issue>No</safety_issue>
    <description>OBL is a complication that can occur during femtosecond flap creation.  If present, OBL will be assessed at the time of surgery by digital photo analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal flap thickness as assessed by ocular coherence tomography (OCT)</measure>
    <time_frame>Month 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>The thickness of the corneal flap will be assessed by OCT (ie, an imaging method using light to capture three-dimensional images). Corneal flap thickness is measured in microns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity (UCVA)</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>UCVA (ie, without spectacles) will be performed at a distance of four meters. UCVA is measured in logMAR (minimum angle of resolution), with a lower logMAR indicating better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>BCVA (ie, with spectacles or other visual corrective devices) will be performed at a distance of four meters. BCVA is measured in logMAR (minimum angle of resolution), with a lower logMAR indicating better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manifest refraction per standard of care</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>A series of test lenses in graded powers will be used to determine which corrective lenses provide the sharpest, clearest vision. Manifest refraction is measured in diopters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast Acuity</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Contrast acuity (ie, measurement of shades of gray against a background) will be assessed in accordance with the manufacturer's guidelines. Contrast acuity is measured in logMAR, with a lower logMAR indicating better contrast acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal flap diameter as assessed by ocular coherence tomography (OCT)</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The diameter of the corneal flap will be assessed by OCT (ie, an imaging method using light to capture three-dimensional images). Corneal flap diameter is measured in millimeters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total root square mean (RMS) as determined by wavefront aberrometry</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total root square mean (RMS) as determined by wavefront aberrometry [Time Frame: Up to Month 6] [Designated as safety issue: No]
• Wavefront aberrometry measures the eye's image-forming quality and optical abnormalities and how visual acuity is affected. Total RMS (ie, the overall magnitude of all the eye's refractive errors) will be assessed using a commercially available system. Total RMS is measured in 0.01 microns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectacle independence as reported on the RSVP Questionnaire for Quality of Life and Retreatment</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Refractive Status and Vision Profile (RSVP) Questionnaire measures self-reported vision-related health status in persons with refractive error.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal curvature as measured by keratometry</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corneal curvature will be assessed using a commercially available system. Corneal curvature is measured in diopters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flap creation time as documented in the Log Files</measure>
    <time_frame>Day 0 (operative day)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time to create the flap with FS200 Femtosecond Flap Creation System is measured in seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wavefront optimization profile (WFO) as determined by wavefront aberrometry</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Wavefront aberrometry measures the eye's image-forming quality and optical abnormalities and how visual acuity is affected. WFO profile will be assessed using a commercially available system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal topography</measure>
    <time_frame>Up to Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Corneal topography (ie, variations in the front surface curvature of the cornea) will be assessed using a commercially available system.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>WaveLight® Refractive Suite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LASIK surgery (laser in situ keratomileusis) per standard care of treatment and medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WaveLight® Refractive Suite</intervention_name>
    <description>Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation</description>
    <arm_group_label>WaveLight® Refractive Suite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LASIK surgery</intervention_name>
    <description>Surgical procedure for treating refractive error based on corneal reshaping</description>
    <arm_group_label>WaveLight® Refractive Suite</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to understand and sign an informed consent form.

          -  Have refractive error (in both eyes) that requires refractive surgery.

          -  Willing to undergo LASIK surgery using the Wavelight® Refractive Suite.

          -  Myopia between 0.00 to -12.0 Diopters pre-operatively.

          -  Astigmatism between 0.00 to +6.00 Diopters pre-operatively.

          -  Willing and able to attend post-operative examinations per protocol schedule.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Participation in a clinical study within the last 30 days.

          -  History of previous corneal surgery in either eye.

          -  Multifocal ablations in either eye.

          -  PRK or PTK surgery in either eye.

          -  Suffering from acute or recurring eye diseases in either eye, such as corneal ulcers,
             cataract, etc.

          -  Any ocular disease and/or condition that, in the Investigator's clinical judgment,
             may put subject at significant risk, compromise study results, or interfere
             significantly with subject's participation in the study.

          -  Unable to discontinue contact lens wear as specified in protocol.

          -  History of Herpes simplex or Herpes zoster keratitis.

          -  Active ocular rosacea.

          -  Lyme disease.

          -  Severe ocular allergies.

          -  Other medical conditions and use of medications as specified in protocol.

          -  Pregnant or planning to become pregnant during the study.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefani Smith, MS</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nearsighted</keyword>
  <keyword>astigmatism</keyword>
  <keyword>LASIK</keyword>
  <keyword>refractive surgery</keyword>
  <keyword>WaveLight</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
